ULTRAGENYX PHARMACEUTI

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

21 Dec 2022 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at Piper Sandler Healthcare Conference

22 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 Nov 2022 15:05:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Departure of Chief Financial Officer

10 Nov 2022 15:15:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at Upcoming Healthcare Conferences

09 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update

02 Nov 2022 15:05:01 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update

27 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

04 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR

09 Sep 2022 19:22:15 By Nasdaq GlobeNewswire

Ultragenyx to Participate at Citi BioPharma Conference

01 Sep 2022 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

17 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 Aug 2022 15:05:02 By Nasdaq GlobeNewswire

Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update

28 Jul 2022 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corporate Update

25 Jul 2022 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 Jul 2022 16:09:15 By Nasdaq GlobeNewswire

Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising Interim Data from Phase 1/2 Study

18 Jul 2022 15:00:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets

14 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at Goldman Sachs Global Healthcare Conference

10 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at Jefferies Global Healthcare Conference

01 Jun 2022 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Therapy Studies at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

19 May 2022 07:00:01 By Nasdaq GlobeNewswire